Extended Paxlovid Treatment Shows Potential for Some Long COVID Patients

A small study reveals mixed results, with some patients experiencing symptom relief while others see limited or no benefits.

A case series of 13 patients explored the effects of extended Paxlovid courses (7.5–30 days) for Long COVID treatment.
Five patients reported sustained symptom improvement, while others experienced temporary relief or no change.
Two participants treated during acute reinfections returned to their baseline health after completing extended courses.
Researchers emphasize the need for further studies to identify which patients may benefit and the optimal treatment duration.
Long COVID affects an estimated 1 in 13 adults in the U.S., with over 200 symptoms making treatment development complex.